This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Archemix Corporation. Active years: 2010-2011.
Company Filing History:
Years Active: 2010-2011
Title: The Innovative Contributions of Jess Wagner-Whyte
Introduction
Jess Wagner-Whyte is a notable inventor based in Lynn, MA (US). He has made significant contributions to the field of therapeutics and diagnostics, particularly in relation to coagulation disorders and prostate cancer. With a total of 2 patents, his work has the potential to impact medical treatments and improve patient outcomes.
Latest Patents
Wagner-Whyte's latest patents include two groundbreaking inventions. The first patent focuses on "Aptamers that bind thrombin with high affinity." This invention provides aptamers capable of binding to thrombin, which can be useful as therapeutics for and diagnostics of coagulation-related disorders and other diseases where thrombin is implicated. The invention also outlines materials and methods for the administration of these aptamers. The second patent is titled "Stabilized aptamers to PSMA and their use as prostate cancer therapeutics." This invention offers stabilized, high-affinity nucleic acid ligands to PSMA. It describes methods for identifying and preparing novel, stable, high-affinity ligands to PSMA using the SELEX™ method with 2'-O-methyl substituted nucleic acids, as well as cell surface SELEX™. Additionally, it includes methods and compositions for the treatment and diagnosis of diseases characterized by PSMA expression.
Career Highlights
Wagner-Whyte is currently associated with Archemix Corporation, where he continues to innovate and develop new therapeutic solutions. His work is characterized by a strong focus on creating effective treatments for serious health conditions.
Collaborations
Throughout his career, Jess Wagner-Whyte has collaborated with notable colleagues, including John Louis Diener and Paul Hatala. These collaborations have likely contributed to the advancement of his research and the successful development of his patents.
Conclusion
Jess Wagner-Whyte's contributions to the field of medical therapeutics through his innovative patents demonstrate his commitment to improving healthcare. His work in developing aptamers for thrombin and PSMA highlights the potential for significant advancements in the treatment of coagulation disorders and prostate cancer.